Improving oncolytic viruses for treating pancreatic cancer
Official title: Understanding and improving novel oncolytic viruses for pancreatic cancer
Funded at University of North Carolina Charlotte · NIH-10796294 · Data updated 2026-11-12
This study is looking at a special virus that can help fight pancreatic cancer by targeting and killing cancer cells while leaving healthy cells alone, and it aims to find out why some cancer cells don't respond to this treatment so that we can make it work better for everyone.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $448,536 |
| NIH project number | 1R15CA280729-01A1 |
| Project ID | NIH-10796294 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who may benefit from novel virotherapy treatments.
✕Less likely to help
Patients with non-pancreatic cancers or those who do not have pancreatic ductal adenocarcinoma may not receive any benefit from this research.
What this research studies
This research focuses on developing and enhancing oncolytic viruses, specifically vesicular stomatitis virus (VSV), to target and destroy pancreatic cancer cells. The approach involves using these viruses to infect cancer cells, leading to their destruction while sparing normal tissues. The study aims to understand why some pancreatic cancer cell lines resist treatment with VSV and to identify ways to overcome this resistance. By analyzing the cellular characteristics of various pancreatic cancer lines, the research seeks to improve treatment outcomes for patients with this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with pancreatic cancer.
How similar studies have gone: Previous studies have shown promise with oncolytic viruses in treating various malignancies, indicating potential for success in this novel approach.
Where this research is happening
-
University of North Carolina Charlotte
Charlotte, United States Active
Researchers
- Principal investigator: Grdzelishvili, Valery Zurabovich — University of North Carolina Charlotte
- Study coordinator: Grdzelishvili, Valery Zurabovich
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.